Please assess the completion status of the following clinical trial:

Trial Title: Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed invasive carcinoma of the breast for which adjuvant systemic therapy is appropriate~  * Stage I, II, or IIIA~ * Pathologically positive or negative nodes~ * Any size primary tumor~* No edema, peau d'orange, infiltration of the skin, or direct extension to the chest wall~* Hormone receptor status:~  * Not specified~PATIENT CHARACTERISTICS:~Age:~* Not specified~Sex:~* Female~Menopausal status:~* Pre-, peri-, or postmenopausal~Performance status:~* Not specified~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Other:~* No prior malignancy except:~  * Basal cell carcinoma~ * Carcinoma in situ of the cervix~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* See Disease Characteristics~Chemotherapy:~* See Disease Characteristics~Endocrine therapy:~* See Disease Characteristics~Radiotherapy:~* Not specified~Surgery:~* Not specified~Other:~* No prior systemic treatment for breast cancer

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).